Paul Stockhammer

Heme-Onc Fellow at @YaleCancer. Interested in #HER2 and #EGFR driven lung cancer. #LCSM

[Paul Stockhammer @StockhammerPaul]

Excited for receiving this award from @lcrf_org / @Boehringer to model and study HER2-mutated lung cancer! 🧬🫁
@YaleCancer @SmilowCancer #LCSM

[Lung Cancer Research Foundation @lcrf_org]

Announcing the 2025 LCRF | Boehringer Ingelheim Early Career Investigator Awards: three awardees each received a $250k grant for projects focused on HER2-driven lung cancer. Read more about these scientists and the focus of their studies. https://t.co/F10TCUuMBI

[Yale Hematology Oncology Fellows @YaleHemOnc]

Yale @ConquerCancerFd YIA Winners, past and present! Love the support ❤️@StockhammerPaul @RSharma128 @curtperrymdphd @AdrianaKahnMD

[Daniela Goyes, MD, MHS @dgoyesv]

Grateful to have completed my MHS in Clinical Investigation at @YaleMed 🎓

Thankful to my mentors at @YaleDigestive, colleagues, family, and friends for their support throughout this journey ✨ excited for what comes next!

#MHS #Yale #MedTwitter

[Yale Hematology Oncology Fellows @YaleHemOnc]

Meeting of the minds this morning at ASCO!

[Yale Hematology Oncology Fellows @YaleHemOnc]

Several of our thoracic fellows spent the day at the @OncLive Lung Fellows Forum and one of them showed his hidden talent in ping pong!

[Daniela Goyes, MD, MHS @dgoyesv]

A meaningful milestone in my training. Grateful for the opportunity to learn from exceptional mentors and colleagues @YaleMed @YaleDigestive and for the experiences that have shaped my growth as a clinician and investigator 🎓

[Paul Stockhammer @StockhammerPaul]

Excited to be a recipient of a @ConquerCancerFd YIA this year! Thankful for my mentors @YaleCancer @YaleMed @YaleHemOnc #LCSM 🫁🧑‍🔬

[Conquer Cancer, the ASCO Foundation @ConquerCancerFd]

We're thrilled to officially announce the 2026 class of Conquer Cancer Grants and Awards recipients! 🔬 These grants empower the next generation of physician-scientists to turn innovative ideas into clinical breakthroughs. Congratulations to the new class—see you in Chicago for #ASCO26!

Full list of recipients here: https://t.co/Ltov9bTGYi

#ResearchConquersCancer #ConquerCancer @ASCO

[Yale Hematology Oncology Fellows @YaleHemOnc]

A huge congratulations to our fellows Drs. Nassar, Sharma, and Stockhammer for their incredible work!

[Paul Stockhammer @StockhammerPaul]

@UrsWeberMD @YaleCancer @ConquerCancerFd @MaryamMooghali @AminNassarMD @SmilowCancer @ASCO Thanks, @UrsWeberMD

[Yale Cancer Center @YaleCancer]

We are excited to share the @YaleCancer recipients of @ConquerCancerFd awards. Congratulations to Drs. Krishna Iyer; Caroline Richburg; Rajal Sharma; @StockhammerPaul; Shira Gabizon Peretz; @MaryamMooghali; and @AminNassarMD!
https://t.co/VzjAyRn3u2
@SmilowCancer @ASCO #ASCO26 @YaleHemOnc

[Benjamin Levy @benlevylungdoc]

Thank you fellows, faculty, and OncLive for an outstanding day of learning, collaboration, and networking. Inspiring discussions, new connections, and a shared commitment to advancing care. The future is bright! @OncLive @StephenVLiu @drshieldsmd @PatelOncology

[Yale Cancer Center @YaleCancer]

Research presented by Mariana Do Carmo @yalepathology shows tumor suppressor gene loss plays a major role in how EGFR-mutant #lungcancer grows and responds to therapy. Certain gene losses can accelerate tumor growth or drive resistance to EGFR inhibitors. #AACR26 @AACR @SmilowCancer @OncoAlert @StockhammerPaul

[Stephen V Liu, MD @StephenVLiu]

Looking forward to joining the #ASCO26 @OncLive National Fellows Forum with Drs. @benlevylungdoc @DrJNaidoo @drshieldsmd @PatelOncology @christine_lovly. Fellows can apply below - selection includes travel and hotel for the May 28 forum!

https://t.co/kw56jPdxae

[Urs Weber MD @UrsWeberMD]

Ross Camidge’s incredible presentation from #TTLC26 is now available online. Anyone who deals with cancer in any capacity should watch it. You might cry (I did) but it’s worth it. Thank you @IASLC for making the presentation publicly available.

https://t.co/GIn7KqMAZ5

[Oscar Tahuahua @OscarTahuahua]

Do HER2 mutant #NSCLC tumors progressing on T DXd lose HER2 dependence?

No. Resistance is mainly driven by payload related mechanisms such as SLFN11 loss or ABCC1 gain, or impaired antibody binding due to domain IV mutations, rather than loss of the HER2 driver.

HER2 signaling persists, and tumors retain sensitivity to #HER2 TKIs (zongertinib/poziotinib). Progression on #TDXd opens a rational path to TKIs
https://t.co/YCVPBankzU @OncoAlert @AndresFCardonaZ

[Stephen V Liu, MD @StephenVLiu]

Results from part 1 of phase Ib DESTINY-Lung03: trastuzumab deruxtecan (T-DXd, HER2 ADC) in HER2 overexpressing NSCLC @JTOonline. Monotherapy (n=36) RR 44.4% with serious AEs in 16.7%. Combo with durvalumab + carbo (n=24) RR 37.5%, serious AEs in 37.5%.

https://t.co/Ew9Kttcu5s

[Eric K. Singhi, MD @lungoncdoc]

Grateful to see these @US_FDA approvals for our patients with lung cancer!

[Oncology Brothers @OncBrothers]

2025 approvals: Summary of 9 new drugs/indications in #LungCancer by @US_FDA

1. #TelisoV
2. #Taletrectinib
3. #DatoDXd
4. #Sunvozertinib
5. #Zongertinib
6. #Lurbinectedin (w/Atezo)
7. #Sevabertinib
8. #Tarlatamab
9. SubQ #Amivantamab

#lcsm #OncTwitter #MedTwitter

[Paul Stockhammer @StockhammerPaul]

@MarkDSiegel1 @TradIMYale @YaleHemOnc @SmilowCancer @YaleCancer Thank you @MarkDSiegel1 !

[Paul Stockhammer @StockhammerPaul]

@TalalZarif1 @uclaCVfellows @TradIMYale @MarkSiegel Congrats, Talal!!